US FDA Panel Votes Against Data That Merck's Drug Provides Clinically Meaningful Benefit To Chronic Cough Patients
Portfolio Pulse from Benzinga Newsdesk
A US FDA panel has voted against the data suggesting that Merck's drug provides a clinically meaningful benefit to patients with chronic cough, according to Reuters.

November 17, 2023 | 9:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The FDA panel's negative vote on the efficacy of Merck's chronic cough drug could negatively impact investor sentiment and Merck's stock price in the short term.
The FDA panel's vote is a significant regulatory hurdle and could imply delays or challenges in getting approval for the drug. This can affect Merck's revenue projections for the drug and potentially lead to negative investor sentiment, thus impacting the stock price negatively in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90